Published in J Invest Dermatol on September 01, 1983
Epidermal keratinocyte Ia expression, Langerhans cell hyperplasia and lymphocytic infiltration in skin lesions of leprosy. Clin Exp Immunol (1986) 0.93
Immunohistological evidence of lymphokine production and lymphocyte activation antigens in tuberculin reactions. Clin Exp Immunol (1987) 0.82
Langerhans' cells and subtypes of human papillomavirus in cervical intraepithelial neoplasia. BMJ (1988) 0.82
In situ localization of interferons in psoriatic lesions. Arch Dermatol Res (1989) 0.82
Cellular kinetics of delayed hypersensitivity test reactions to topical glucocorticosteroids. Arch Dermatol Res (1987) 0.75
Immunophenotyping of the cellular infiltrate in the early elicitation phase of contact dermatitis in the skin of presensitized atopic individuals. Arch Dermatol Res (1995) 0.75
Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme. Lancet (1998) 4.46
Reasons for poor prognosis in British patients with cutaneous malignant melanoma. Br Med J (Clin Res Ed) (1986) 2.49
Severe sunburn and subsequent risk of primary cutaneous malignant melanoma in scotland. Br J Cancer (1982) 2.49
Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet (2001) 2.40
Experience of a public education programme on early detection of cutaneous malignant melanoma. BMJ (1988) 2.36
Malignant melanoma in Scotland 1979-1983. Lancet (1985) 2.30
Sentinel lymph node biopsy in cutaneous melanoma: the WHO Melanoma Program experience. Ann Surg Oncol (2000) 1.92
Benign melanocytic naevi as a risk factor for malignant melanoma. Br Med J (Clin Res Ed) (1986) 1.88
Clinical recognition of early invasive malignant melanoma. BMJ (1990) 1.75
The number and distribution of benign pigmented moles (melanocytic naevi) in a healthy British population. Br J Dermatol (1985) 1.75
Risk of cutaneous melanoma associated with pigmentation characteristics and freckling: systematic overview of 10 case-control studies. The International Melanoma Analysis Group (IMAGE). Int J Cancer (1995) 1.68
Sunbeds in current use in Scotland: a survey of their output and patterns of use. Br J Dermatol (1998) 1.62
Histopathologic diagnosis of dysplastic nevi: concordance among pathologists convened by the World Health Organization Melanoma Programme. Hum Pathol (1991) 1.54
Genetic and environmental influences in the development of multiple primary melanoma. Arch Dermatol (1999) 1.54
Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol (1997) 1.52
Serum lipid elevation during isotretinoin therapy for acne in the west of Scotland. Br J Dermatol (1990) 1.44
Cutaneous malignancy in males treated with photochemotherapy. Lancet (1990) 1.44
Fluorescent lights, ultraviolet lamps, and risk of cutaneous melanoma. BMJ (1988) 1.41
Risk of cutaneous melanoma associated with a family history of the disease. The International Melanoma Analysis Group (IMAGE). Int J Cancer (1995) 1.38
Cancer, warts, and sunshine in renal transplant patients. A case-control study. Lancet (1984) 1.34
Early diagnosis of infantile seborrhoeic dermatitis and atopic dermatitis--total and specific IgE levels. Br J Dermatol (1983) 1.24
An aid to the preoperative assessment of pigmented lesions of the skin. Br J Dermatol (1971) 1.21
Incidence in South-west Scotland of hepatitis B surface antigen in the liver of patients with hepatocellular carcinoma. J Clin Pathol (1977) 1.20
Comparison of red and green light in the treatment of Bowen's disease by photodynamic therapy. Br J Dermatol (2000) 1.17
Intralesional injection of herpes simplex virus 1716 in metastatic melanoma. Lancet (2001) 1.17
Use of NK1 C3 monoclonal antibody in the assessment of benign and malignant melanocytic lesions. J Clin Pathol (1984) 1.14
Multiple melanoma and atypical melanocytic naevi--evidence of an activated and expanded melanocytic system. Br J Dermatol (1982) 1.12
Utility of adjuvant systemic therapy in melanoma. Ann Oncol (2009) 1.10
Early diagnosis of infantile seborrhoeic dermatitis and atopic dermatitis--clinical features. Br J Dermatol (1983) 1.08
Proposed alternative terminology and subclassification of so called "dysplastic naevi". J Clin Pathol (1986) 1.07
Loss of heterozygosity in malignant melanoma at loci on chromosome 11 and 17 implicated in the pathogenesis of other cancers. Genes Chromosomes Cancer (1993) 1.05
Initial event in mycosis fungoides of the skin is viral infection of epidermal Langerhans cells. Lancet (1981) 1.03
Validity of the histopathological criteria used for diagnosing dysplastic naevi. An interobserver study by the pathology subgroup of the EORTC Malignant Melanoma Cooperative Group. Eur J Cancer (1993) 1.01
The management of acid-related dyspepsia in general practice: a comparison of an omeprazole versus an antacid-alginate/ranitidine management strategy. Compete Research Group [corrected]. Aliment Pharmacol Ther (1998) 1.01
Loss of beta2 microglobulin from the cell surface of cutaneous malignant and premalignant lesions. Br J Dermatol (1981) 0.98
Heterogeneity of chemosensitivity of metastatic cutaneous melanoma. Anticancer Drugs (1999) 0.97
Synthetic retinoids for acne. Lancet (1980) 0.96
Nebulized budesonide versus oral steroid in severe exacerbations of childhood asthma. Acta Paediatr (1999) 0.95
The pathogenesis of cutaneous malignant melanoma. Br Med J (Clin Res Ed) (1983) 0.94
Localization of elevated transforming growth factor-alpha in psoriatic epidermis. J Invest Dermatol (1990) 0.93
Cutaneous malignant melanoma in Scotland. Br J Cancer (1982) 0.93
Treatment of extensive virus warts with etretinate (Tigason) in a patient with sarcoidosis. Clin Exp Dermatol (1983) 0.92
CDKN2A mutations in Scottish families with cutaneous melanoma: results from 32 newly identified families. Br J Dermatol (2005) 0.92
Photodynamic therapy for large or multiple patches of Bowen disease and basal cell carcinoma. Arch Dermatol (2001) 0.90
The effects of thermal stimulation on the ultrastructure of the human atrichial sweat gland. I. The fundus. Br J Dermatol (1984) 0.90
Photodynamic therapy for basal cell carcinoma: effect of tumor thickness and duration of photosensitizer application on response. Arch Dermatol (1998) 0.90
Basal cell cytoplasmic autoantibodies in oral lichenoid reactions. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (1995) 0.89
Melanoma in people aged 65 and over in Scotland, 1979-89. BMJ (1992) 0.89
The distribution and quantification of the Langerhans cell in normal human epidermis. Clin Exp Dermatol (1986) 0.88
A case of bullous pemphigoid and figurate erythema in association with metastatic spread of carcinoma. Br J Dermatol (1973) 0.87
Dissociation of HLA heavy chain and light chain (beta 2 microglobulin) expression on the cell surface of cutaneous malignancies. Br J Dermatol (1983) 0.87
Evaluation of the use of tyrosinase-specific and melanA/MART-1-specific reverse transcriptase-coupled--polymerase chain reaction to detect melanoma cells in peripheral blood samples from 299 patients with malignant melanoma. Br J Dermatol (2001) 0.87
The use of BELD combination chemotherapy (bleomycin, vindesine, CCNU, and DTIC) in advanced malignant melanoma. Cancer (1985) 0.86
Bambuterol: effective in nocturnal asthma. Respir Med (1993) 0.86
Validation of in vitro chemosensitivity testing in malignant melanoma. Lancet (1983) 0.86
An assessment of the diagnostic value of the monoclonal antibodies Leu 8, OKT9, OKT10 and Ki67 in cutaneous lymphocytic infiltrates. Br J Dermatol (1986) 0.85
Development of melanocytic nevi in the first three years of life. J Natl Cancer Inst (2000) 0.84
Comparison of five antimelanoma antibodies for identification of melanocytic cells on tissue sections in routine dermatopathology. J Am Acad Dermatol (1989) 0.84
Transepidermal elimination of urate-like crystals: a new perforating disorder? Br J Dermatol (1999) 0.84
Relation between phenotype and banal melanocytic naevi. Br Med J (Clin Res Ed) (1987) 0.84
Multiple primary melanoma: risk factors and prognostic implications. BMJ (1994) 0.84
Benign naevi associated with high risk of melanoma. Lancet (1984) 0.84
An evidence base for reconsidering current follow-up guidelines for patients with cutaneous melanoma less than 0.5 mm thick at diagnosis. Br J Dermatol (2008) 0.83
Cerebral metastases of cutaneous melanoma. Br J Cancer (1997) 0.83
Intestinal permeability and atopic disease. Lancet (1981) 0.83
Growth hormone levels in psoriasis. Arch Dermatol Res (1983) 0.83
Studies in cutaneous immunofluorescence. II. Histological and direct immunofluorescence observations in clinically normal skin of patients with rheumatoid arthritis. J Cutan Pathol (1981) 0.82
The pharmacokinetic advantages of isolated limb perfusion with melphalan for malignant melanoma. Br J Cancer (1992) 0.82
Langerhans' cells and subtypes of human papillomavirus in cervical intraepithelial neoplasia. BMJ (1988) 0.82
Maintenance treatment for gastro-oesophageal reflux disease. A placebo-controlled evaluation of 10 milligrams omeprazole once daily in general practice. Scand J Gastroenterol (1997) 0.82
Keratin expression in normal skin and epidermal neoplasms demonstrated by a panel of monoclonal antibodies. J Cutan Pathol (1992) 0.81
Sun and skin damage. J Intern Med (1993) 0.81
Melphalan concentration and distribution in the tissues of tumour-bearing limbs treated by isolated limb perfusion. Eur J Cancer (1992) 0.81
Managing the dysplastic naevus. Lancet (1983) 0.81
The staphylococcal scalded skin syndrome in two elderly immunocompromised patients. Br Med J (Clin Res Ed) (1987) 0.80
Nine years' experience of BELD combination chemotherapy (bleomycin, vindesine, CCNU and DTIC) for metastatic melanoma. Br J Dermatol (1992) 0.80
Experience with the colony-forming (stem cell) assay of in vitro chemosensitivity in the management of patients with advanced malignant melanoma. Cancer Treat Rep (1984) 0.80
The use of a double-label immunoperoxidase monoclonal antibody technique in the investigation of patients with mycosis fungoides. Br J Dermatol (1982) 0.80
Cell-cell and cell-extracellular matrix interactions during melanoma cell invasion and metastasis. Melanoma Res (1993) 0.80
Tamoxifen as a single agent for advanced melanoma in postmenopausal women. A phase II study of the EORTC Malignant Melanoma Cooperative Group. Melanoma Res (1992) 0.79
Gamma-interferon in evolving allergic contact dermatitis reactions. Br J Dermatol (1996) 0.79
Malignant melanoma of the head and neck in Scotland: an eight-year analysis of trends in prevalence, distribution and prognosis. Q J Med (1987) 0.79
Measurement of daylight UVA in Glasgow. Phys Med Biol (1983) 0.79
Melanoma cell-derived factor stimulation of fibroblast glycosaminoglycan synthesis--the role of platelet-derived growth factor. Eur J Cancer (1999) 0.78
A single centre's 10 year experience with isolated limb perfusion in the treatment of recurrent malignant melanoma of the limb. Eur J Cancer (1996) 0.78
A case of pagetoid reticulosis bearing the T cytotoxic suppressor surface marker on the lymphoid infiltrate: further evidence that pagetoid reticulosis is not a variant of mycosis fungoides. Br J Dermatol (1984) 0.78
A study of HLA antigen distribution in families with atopic dermatitis. Allergy (1979) 0.78
Modulation of melanoma cell adhesion to basement membrane components by retinoic acid. J Cell Sci (1989) 0.78
A monoclonal antibody technique to demonstrate an increase in Langerhans cells in cutaneous lesions of mycosis fungoides. Clin Exp Dermatol (1982) 0.78
Effect of maintenance chemotherapy in childhood on numbers of melanocytic naevi. BMJ (1992) 0.78
The phototumorigenic potential of broad-band (270-350 nm) and narrow-band (311-313 nm) phototherapy sources cannot be predicted by their edematogenic potential in hairless mouse skin. J Invest Dermatol (1995) 0.78
The effects of thermal stimulation on the ultrastructure of the human atrichial sweat gland. II. The duct. Br J Dermatol (1985) 0.78
Rising levels of serum S100 protein precede other evidence of disease progression in patients with malignant melanoma. Br J Dermatol (2000) 0.78
The use of paraffin-processed tissue and the immunoperoxidase technique in the diagnosis of bullous diseases, lupus erythematosus and vasculitis. Br J Dermatol (1982) 0.78
The effect of oral retinoid therapy on the normal human immune system. Br J Dermatol (1988) 0.78
A comparison of dosimetric methods in isolated limb perfusion with melphalan for malignant melanoma of the lower extremity. Eur J Cancer (1996) 0.78
Comparison between lentigo maligna melanoma and other histogenetic types of malignant melanoma of the head and neck. Scottish Melanoma Group. Br J Cancer (1996) 0.78
Thickness and delay in diagnosis of melanoma: how far can we go? Arch Dermatol (1999) 0.77
Total and specific IgE levels in patients with atopic dermatitis. The correlation between prick testing, clinical history of allergy, and in vitro quantification of IgE during clinical exacerbation and remission. Clin Exp Dermatol (1979) 0.77
Interferon-alpha for atopic dermatitis. Lancet (1990) 0.77